For the seventh consecutive year, Redeye is organizing an event focusing on drug development in neurology and brain diseases. The event starts with an introduction to the topic and then continues with company presentations.

Alzinova's CEO Tord Labuda will present the company and talk about the latest progress at 11.20 am. The event, which takes place on October 23, will be broadcast live and Alzinova's presentation can be seen on Redeye's website live via: https://www.redeye.se/events/1016173/redeye-theme-neurology-2

The presentation will also be available on Alzinova's website afterwards via the following link: https://www.alzinova.com/investors/presentations/.

For more information, please contact:
Tord Labuda, CEO
Tel: +46 (0)70 838 23 23
E-mail: tord.labuda@alzinova.com

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com